Home›Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate›Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate + Indinavir

Does Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate Interact with Indinavir?

CDI records a unknown classification for Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and Indinavir. The stored summary is: Protease inhibitor: indinavir ↓ indinavir The optimal dose of indinavir, when given in combination with EFV, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to EFV. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Evidence status

A current label comparison is not yet available for this record. The summary and severity are stored CDI information; they have not been independently validated on this page against the exact product label.

Confirm the medicine, formulation, route, and applicable warning with your pharmacist or prescriber. Independent clinical review has not been recorded.

Stored CDI classification: Unknown
Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate Class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Management: Confirm exact products with your pharmacist
Data Source: U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and your doctor is considering prescribing Indinavir (or vice versa), make sure to:

Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
Ask whether the benefits of combining these medications outweigh the risks for your specific situation
Ask what symptoms to watch for that would indicate the interaction is causing problems
Never stop or change either medication without first consulting your healthcare provider

💊 Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate(Atripla)+💊 Indinavir

Severity & Interaction Details

ℹ️

unknown

Stored CDI classification: unknown

A current source comparison has not been recorded for this claim. The stored classification does not determine the clinical significance for your exact products or circumstances.

Severity scale

MinorContra

On record

Yes

Drug A class

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor

Drug B class

—

Source

FDA drug label - efavirenz, emtricitabine and tenofovir disoproxil fumarate

What this means in plain English

Protease inhibitor: indinavir ↓ indinavir The optimal dose of indinavir, when given in combination with EFV, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to EFV.

About Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and Indinavir

Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate is a Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor. Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate is also sold under the brand name Atripla. Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - efavirenz, emtricitabine and tenofovir disoproxil fumarate

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

PubMed

Hypertension in a randomized trial of dolutegravir- versus efavirenz-based antiretroviral therapy in pregnant and postpartum women with HIV.about Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate · 2026-04

PubMed

Hyperlipidemia and associated risk factors among people living with HIV on antiretroviral therapy: a retrospective cohort study from Eastern China.about Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate · 2026-04

PubMed

Efficacy and safety of bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF) versus efavirenz, lamivudine, and tenofovir disoproxil fumarate (EFV+3TC + TDF) in late-presenting people with HIV rapid initial antiretroviral therapy.about Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate · 2026-03

PubMed

Predictive modeling of influenza strain drugs using temperature-based topological indices and regression analysis via multi-criteria decision making techniques.about Indinavir · 2026-03

PubMed

From virtual screening to animal models: chlorhexidine and indinavir as promising anti-Zika drug candidates.about Indinavir · 2026-01

Share this result:

WhatsApp Text / SMS Email

Also share on:X Facebook

Add more drugs

Check Efavirenz Emtricitabine And Tenofovir Disoproxil Fumarate and Indinavir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.